Sage Journals: Discover world-class research

Abstract

Abnormal aromatase (CYP19A1) expression may participate in prostate cancer (PCa) carcinogenesis. However, the results of studies on the CYP19A1 gene polymorphisms and PCa are conflicting. This meta-analysis aimed to systematically evaluate the associations between the CYP19A1 Arg264Cys polymorphism and the (TTTA)n repeat polymorphism and PCa. Electronic databases (PubMed, EmBase, ScienceDirect, and Cochrane Library) were comprehensively searched to identify eligible studies. The strength of the association between the Arg264Cys polymorphism and PCa was assessed by pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) in allelic, dominant, recessive, homozygous, and heterozygous genetic models. To analyze the impact of the (TTTA)n repeat polymorphism, we sequentially took the N-repeat allele (where N equals 7,8,10,11,12, and 13) as the minor allele and the sum of all the other alleles as the major allele. The ORs and 95% CIs were calculated in the allelic model; this analysis was performed individually for each repeat number. Pooled estimates of nine studies addressing the Arg264Cys polymorphism indicated that this polymorphism was not associated with PCa risk in the overall population or in the Caucasian or Asian subgroups. The 8-repeat allele in the (TTTA)n repeat polymorphism increased PCa risk in the overall population (OR = 1.34, 95% CI = 1.14–1.58, p = .001) and in the subgroup with population-based (PB) controls (OR = 1.41, 95% CI = 1.13–1.74, p = .002) as well as in the subgroup using capillary electrophoresis to identify this polymorphism (OR = 1.34, 95% CI = 1.09–1.65, p = .006).The meta-analysis indicated that the CYP19A1 (TTTA)n repeat polymorphism, but not the Arg264Cys polymorphism, may affect PCa risk.

Keywords

CYP19A1 polymorphism prostate cancer meta-analysis

Prostate cancer (PCa), the most common noncutaneous cancer in males, is the second leading cause of cancer death in the United States and represents a major public health challenge (Siegel et al., 2018). The carcinogenesis of PCa is multifactorial, and its details remain obscure. In addition to age, race, obesity, geography, smoking, certain lifestyle factors, radiation, and urinary tract infections, genetic susceptibility is also considered a candidate risk factor for PCa (Cuzick et al., 2014). Men whose first-degree relatives suffer from PCa have a higher risk of this malignancy than those without affected first-degree relatives, and the risk is even higher when these men are younger than 65 years (Kicinski et al., 2011). The prevalence and prognosis of PCa vary among racial groups, and the incidence and mortality are highest in men of African descent (Shenoy et al., 2016). These findings highlight the possible function of genetic factors in PCa. Multiple genes, including the RANSEL, MSR1, HOXB13, CHD5, and EPHB2 genes, have been reported to be associated with susceptibility to PCa (Boyd et al., 2012). Insights into genetic risk factors underlying PCa may help to identify the high-risk population.

PCa is androgen-dependent, and estrogens provide protection against PCa because of their anti-androgenic effects. In contrast to females, in whom estrogens are secreted by a central organ (ovaries), the main source of estrogens in males is the peripheral conversion of androgen precursors (Rahman et al., 2016). The enzyme aromatase (CYP19A1), mainly expressed in the gonads and peripheral tissues, including the prostate, is essential for the conversion of androgens to estrogens and represents an important therapeutic target in breast cancer (Rahman et al., 2016; Regan et al., 2011). Aberrant aromatase expression was detected in PCa tissue but not in benign prostate hyperplasia (BPH) tissue and may contribute to the recurrence of PCa (Celhay et al., 2010; Ellem et al., 2004; Gianfrilli et al., 2014). Liang and coworkers documented that CYP19A1 expression was significantly higher in castration-resistant prostate cancer (CRPC) than in primary PCa, and patients with elevated CYP19A1 expression had shorter overall survival after first hormone therapy than patients with lower expression (Liang et al., 2019). The level of CYP19A1 expression was also correlated with the Gleason score in primary PCa patients (Liang et al., 2019). These findings suggest that CYP19A1 might contribute to the onset, development, and prognosis of PCa and its response to treatment. CYP19A1 is encoded by the CYP19A1 gene mapped to chromosome 15q21.2 (Sebastian & Bulun, 2001). Although the polymorphism of the CYP19A1 gene is related to the levels of sex hormones, including testosterone, in men with and without PCa, the impact of polymorphisms of this gene on PCa remains controversial (Kanda et al., 2015; Travis et al., 2009). Several studies have focused on the associations between the Arg264Cys polymorphism (rs700519) in exon 7 and the tetranucleotide simple tandem (TTTA)n repeat polymorphism in intron 4 of the CYP19A1 gene and PCa, but the results were not unequivocal (Modugno et al., 2001; Onsory et al., 2008; Soni et al., 2012; Suzuki et al., 2003). Therefore, we performed a meta-analysis to investigate the effects of these two polymorphisms in PCa more comprehensively.

Methods

Literature Search

The electronic databases of PubMed, EmBase, ScienceDirect, and Cochrane Library were searched comprehensively and systematically by two independent investigators from inception to December 31, 2020 to identify relevant studies. The key words applied were “CYP19A1,” “aromatase,” “rs700519,” “Arg264Cys,” “R264C,” “TTTA” and “polymorphism” in combination with “prostate cancer” or “prostatic neoplasms.” Reference lists in the retrieved publications were also manually screened for potentially eligible studies.

Inclusion and Exclusion Criteria

The inclusion criteria were as follows: (1) case-control, cross-sectional, or nested case-control studies on the CYP19A1 Arg264Cys polymorphism and/or (TTTA)n repeat polymorphism in PCa; (2) studies published in English; and (3) studies with adequate allele and genotype data for both the cases and the controls to calculate the odds ratios (ORs) and 95% confidence intervals (CIs). In the case of overlapped subjects in different studies, only the most complete study was involved.

The exclusion criteria were as follows: (1) reviews, meta-analyses, or case reports; (2) case-only or family-based studies; (3) studies with intervention strategies that might modify the risk of PCa; (4) studies not providing allele/genotype frequencies or adequate data allowing their calculation; (5) studies on the polymorphisms of other genes or other prostate diseases; (6) duplicate publications; and (7) publications written in languages other than English.

Data Extraction and Quality Assessment

Two investigators independently extracted the following data from selected studies: the first author’s name, publication year, study design, ethnicity and country of the study population, source of controls, sample size, age of cases and controls, sample acquisition and genotyping method, allele and genotype distributions in each polymorphism (stated in the publication or calculated from the study data using standard formulae). Disagreements were resolved by discussing and consulting the third investigator. The Newcastle–Ottawa Scale (NOS) was used to assess the quality of case-control and nested case-control studies (Stang, 2010), and studies scoring six or more stars were considered to have a high quality (Piovezan et al., 2019).

Statistical Analysis

The meta-analysis was conducted with STATA software 12.0 (STATA Corp., College Station, TX, USA). In each study, the Hardy-Weinberg equilibrium (HWE) in the control group was tested by the Pearson chi-square test. To evaluate the strength of the association between the Arg264Cys polymorphism and PCa, pooled ORs with corresponding 95% CIs were calculated in five genetic models: allelic (T vs. C), dominant (CT + TT vs. CC), recessive (TT vs. CT + CC), homozygous (TT vs. CC), and heterozygous (CT vs. CC) models. For the (TTTA)n repeat polymorphism, the N repeat allele (with N equal to 7, 8, 10, 11, 12, and 13, sequentially) was considered the minor allele, and all the other alleles were added together as the major allele. The ORs and 95% CIs were calculated in the allelic model. The significance of ORs was determined by the Z-test, and p < .05 was considered statistically significant. Heterogeneity among studies was assessed by the I² statistic. . When I² was less than 50%, the fixed-effect model (the Mantel–Haenszel method) was applied. Otherwise, the random-effects model (the DerSimonian and Laird method) was used. Additionally, subgroup analyses were performed. Sensitivity analysis was conducted to assess the stability of the pooled results; individual studies were omitted one at a time, and the pooled results were recalculated. Begg’s funnel plots and Egger’s linear regression test were conducted to detect potential publication bias (Langhorne, 1998); an asymmetric funnel plot suggests a possible publication bias and p < .05 in Egger’s test indicates significant publication bias (Egger et al., 1997).

Results

Selection and Characteristics of Eligible Studies

According to the inclusion and exclusion criteria, a total of 14 studies (Fukatsu et al., 2004; Holt et al., 2013; Huang et al., 2007; Kachakova et al., 2016; Modugno et al., 2001; Onsory et al., 2008; Price et al., 2016; Sarma et al., 2010; Soni et al., 2012; Sonoda et al., 2010; Suzuki, Nakazato, Matsui, Koike, Okugi, Kashiwagi, et al., 2003; Suzuki, Nakazato, Matsui, Koike, Okugi, Ohtake, et al., 2003; Tang et al., 2011; Travis et al., 2009) were deemed eligible for this meta-analysis (Figure 1 details the study selection process). Among them, eight studies investigated only the Arg264Cys polymorphism (Fukatsu et al., 2004; Holt et al., 2013; Modugno et al., 2001; Onsory et al., 2008; Price et al., 2016; Sarma et al., 2010; Suzuki, Nakazato, Matsui, Koike, Okugi, Kashiwagi, et al., 2003; Travis et al., 2009), five studies explored only the (TTTA)n repeat polymorphism (Huang et al., 2007; Soni et al., 2012; Sonoda et al., 2010; Suzuki, Nakazato, Matsui, Koike, Okugi, Ohtake, et al., 2003; Tang et al., 2011), and one study focused on both polymorphisms (Kachakova et al., 2016). The main characteristics of these studies are listed in Tables 1 and 2. With the exception of the work of Fukastu et al. (2004) with a score of 5, all studies were considered of high quality based on NOS ≥ 6.

Figure 1.

Selection of studies for this meta-analysis.

Table 1.

Main Characteristics of Studies About the CYP19A1 Arg264Cys Polymorphism and Prostate Cancer.

First author	Country	Ethnicity	Study design	Source of control	Sample size				Age case/control	Sample acquisition	Genotyping method	HWE	NOS
First author	Country	Ethnicity	Study design	Source of control	Total cases	Unselected cases	Familial cases	Control	Age case/control	Sample acquisition	Genotyping method	HWE	NOS
Modugno (2001)	America	Caucasian	Case-control	PB	88	NA	NA	241	68.9/73.6	Peripheral blood	PCR-RFLP	1.00	6
Suzuki (2003)	Japan	Asian	Case-control	HB	101	0	101	114	69.8/71.2	Peripheral blood	PCR-SSCP	0.14	6
Fukatsu (2004)	Japan	Asian	Case-control	HB	107	NA	NA	187	71.3 ± 8.3/70.4 ± 7.5	Peripheral blood in all cases; Peripheral blood or frozen prostate tissue in controls	PCR-RFLP	0.19	5
Sarma (2008)	America	African-American	Case-control	PB	131	103	28	341	67.2 ± 8.6/62.1 ± 10.1	Peripheral blood	High-throughput genotyping	0.45	6
Onsory (2008)	India	Indian	Case-control	HB	100	NA	NA	100	NA	Peripheral blood or frozen prostate tissue	PCR-RFLP	<0.01	7
Travis (2009)	AmericaEurope	mixed	Nested case-control	PB	8919	NA	NA	8038	68/68	Peripheral blood	TaqMan	<0.01	7
Holt (2013)	America	Caucasian	Case-control	PB	1272	NA	NA	1247	35–74/35–74	Peripheral blood	SNPlex^TM Genotyping System	1.00	7
Kachakova (2016)	Bulgaria	Caucasian	Case-control	HB &PB	241	NA	NA	261	69.25/NA	Peripheral blood	PCR-RFLP PCR-SSCP	0.31	6
Price^# (2016)	America	Caucasian	Nested case-control	PB	865	NA	NA	839	63.96/63.74	Peripheral blood	TaqMan	1.00	6

Note. PB = population based; HB = hospital based; HWE = Hardy-Weinberg equilibrium; PCR = polymerase chain reaction; RFLP = restriction-fragment length polymorphism; SSCP = single-strand conformation polymorphism; BPH = benign prostate hyperplasia; NA = not available; NOS = the Newcastle-Ottawa Scale.

A nested case-control study, in which the intervention measures might have influenced the risk of prostate cancer; only the placebo arm data were used.

Table 2.

Main Characteristics of Studies About the CYP19A1 (TTTA)n Repeat Polymorphism and Prostate Cancer.

First author	Country	Ethnicity	Source of control	Sample size case/control	Age case/control	Genotyping method	(TTTA)n repeat allele frequency (case/control)								NOS
First author	Country	Ethnicity	Source of control	Sample size case/control	Age case/control	Genotyping method	7	8	9	10	11	12	13	14	NOS
Suzuki (2003)	Japan	Asian	HB	99/116	70/71.2	PCR and ethidiumbromide staining	53/62	85/81	0/0	5/9	40/53	15/26	0/1	0/0	6
Huang (2007)	China	Asian	HB	244/261	73.1 ± 7.0/73.4 ± 7.7	PCR-RFLP	273/279	2/3	0/0	10/4	173/184	30/51	0/1	0/0	6
Sonoda (2010)	Japan	Asian	HB	179/166	46–81/45–87	Pyrosequencing technology	229/234	0/3	0/0	1/0	85/70	30/14	13/11	0/0	6
Tang* (2011)	America	Mixed	PB	619/722	35–74/35–74	Capillary electrophoresis	631/759	139/119	0/0	23/19	414/506	31/41	0/0	0/0	6
Soni (2012)	India	Indian	PB	105/105	68.6 ± 9.8/62.0 ± 10.6	PCR-RFLP	48/61	95/78	33/25	0/0	0/0	34/46	0/0	0/0	7
Kachakova (2016)	Bulgaria	Caucasian	HB&PB	242/251	69.3 ± 8.2/NA	Capillary electrophoresis	187/186	78/68	58/63	3/0	7/16	133/152	18/16	0/1	6

Note. PB = population based; HB = hospital based; PCR = polymerase chain reaction; RFLP = restriction fragment length polymorphism; NA = not available; NOS = the Newcastle-Ottawa Scale.

A nested case-control study, in which the intervention measures might have influenced the risk of prostate cancer; only the placebo arm data were used. All other studies are case-control studies.

Association Between the CYP19A1 Arg264Cys Polymorphism and PCa Risk

Nine studies (seven case-control studies and two nested case-control studies), which recruited a total of 11,824 patients and 11,368 control subjects, addressed the relationship between the CYP19A1 Arg264Cys polymorphism and PCa (Table 1) (Fukatsu et al., 2004; Holt et al., 2013; Kachakova et al., 2016; Modugno et al., 2001; Onsory et al., 2008; Price et al., 2016; Sarma et al., 2010; Suzuki, Nakazato, Matsui, Koike, Okugi, Kashiwagi, et al., 2003; Travis et al., 2009). These studies enrolled Caucasians (four studies), Asians (two studies), Indians (one study), African-Americans (one study), and subjects of mixed ethnicities (one study). One study employed intervention measures (finasteride) that might confer PCa risk and might conceal the real situation of this polymorphism in PCa; therefore, only data in the placebo arm in this study were considered (Price et al., 2016). In two studies, genotype distributions in the control groups deviated from HWE (Onsory et al., 2008; Travis et al., 2009). Controls were hospital-based (HB) in three studies, population-based (PB) in five studies, and both HB and PB in one study. One study merely recruited cases with a family history of PCa in a first-degree relative (Suzuki, Nakazato, Matsui, Koike, Okugi, Kashiwagi, et al., 2003), one study described the ratio of familial cases in all participants (Sarma et al., 2010), and the remaining seven studies did not provide information about family history. Peripheral blood was used to detect this polymorphism in seven studies (Holt et al., 2013; Kachakova et al., 2016; Modugno et al., 2001; Price et al., 2016; Sarma et al., 2010; Suzuki, Nakazato, Matsui, Koike, Okugi, Kashiwagi, et al., 2003; Travis et al., 2009), while peripheral blood or frozen prostate tissues were used in the other two studies (Fukatsu et al., 2004; Onsory et al., 2008).

The allele and genotype frequencies in the overall population and all subgroups are summarized in Table 3. The overall pooled results and subgroup analyses are listed in Table 4. Neither the T allele nor the TT genotype was associated with PCa in the overall population, Caucasians, or Asians (Figure 2 displays a nonsignificant association between the T allele and overall PCa risk). Subgroup analyses could not be performed for African-Americans, Indians, or mixed ethnicities since each of these ethnicities was included only in one study. Subgroup analysis stratified by the source of controls was also conducted. When PB controls were considered, no evident association was found between the Arg264Cys polymorphism and PCa in any genetic model. Nevertheless, an association between the Arg264Cys polymorphism and PCa was observed under the dominant model (CT+TT vs. CC: OR = 1.35, 95% CI = 1.02–1.78, p = .04) and heterozygous model (CT vs. TT: OR = 1.40, 95% CI = 1.04–1.88, p = .03) in the HB subgroup. Subgroup analysis could not be accomplished for the PB+HB subgroup since only one study included PB+HB controls. We further conducted subgroup analyses based on the sample acquisition and genotyping method. No significant association was detected in these subgroups (Table 4).

Table 3.

Allele and Genotype Distribution in the CYP19A1 Arg264Cys Polymorphism of Subjects Included in the Meta-Analysis.

	Subgroup (study number)	Sample sizecase/control	Allele frequency case/control		Genotype frequency case/control
	Subgroup (study number)	Sample sizecase/control	C	T	CC	CT	TT
Overall		11824/11368	22162/21260	1486/1476	10453/10021	1256/1218	115/129
Ethnicity	Caucasian (4)	2466/2588	4753/5001	179/175	2290/2415	173/171	3/2
	Asian (2)	208/301	301/464	115/138	113/185	75/94	20/22
	Indian (1)	100/100	155/166	45/34	59/73	37/20	4/7
	African-American (1)	131/341	219/565	43/117	91/236	37/93	3/12
	Mixed population (1)	8919/8038	16734/15064	1104/1012	7900/7112	934/840	85/86
Source of control	PB (4)	10410/9867	19564/18493	1246/1241	9255/8725	1064/1043	91/99
	HB (4)	208/301	301/464	115/138	113/185	75/94	20/22
	PB+HB (1)	865/839	1668/1635	62/43	803/796	62/43	0/0
Genotyping method	PCR-RFLP (3)	295/528	491/926	99/130	206/417	79/92	10/19
	Taqman (2)	9784/8877	18402/16699	1166/1055	8703/7908	996/883	85/86
	PCR-SSCP (1)	101/114	132/171	70/57	45/67	42/37	14/10
	PCR-RFLP&PCR-SSCP (1)	241/261	464/502	18/20	223/242	18/18	0/1
	High-throughput genotyping (1)	131/341	219/565	43/117	91/236	37/93	3/12
	SNPlexTM Genotyping System (1)	1272/1247	2454/2397	90/97	1185/1151	84/95	3/1
Sample acquisition	Peripheral blood (7)	11617/11081	21838/20801	1396/1361	10326/9830	1186/1141	105/110
Sample acquisition	Peripheral blood or frozen prostate tissue (2)	207/287	324/459	90/115	127/119	70/77	10/19

Note. PB = population-based; HB = hospital-based; PCR = polymerase chain reaction; RFLP = restriction fragment length polymorphism; SSCP = single-strand conformation polymorphism.

Table 4.

Meta-Analysis of the Association Between the CYP19A1 Arg264Cys Polymorphism and Prostate Cancer.

Genetic model	Subgroup		Study number	Test of association			I² (%)	Publication bias (P)
Genetic model	Subgroup		Study number	OR	95% CI	p	I² (%)	Begg	Egger
T vs. C	Ethnicity	Overall	9	1.08	0.94–1.24	.27	30.9	0.08	0.10
		Caucasian	4	1.12	0.84–1.48	.44	30.3
		Asian	2	1.24	0.76–2.02	.40	64.6
	Source of control	PB	4	0.98	0.90–1.06	.62	0.0
	Source of control	HB	4	1.23	0.95–1.60	.12	17.5
	Genotyping method	PCR-RFLP	3	1.19	0.87–1.62	.27	6.1
	Genotyping method	Taqman	2	1.12	0.79–1.57	.52	67.8
	Sample acquisition	Peripheral blood	7	1.01	0.94–1.09	.79	38.5
	Sample acquisition	Peripheral blood or frozen prostate tissue	2	1.13	0.82–1.54	.46	27.7
CT+TT vs. CC	Ethnicity	Overall	9	1.13	0.95–1.34	.17	40.6	0.08	0.08
		Caucasian	4	1.13	0.83–1.54	.44	37.1
		Asian	2	1.31	0.73–2.33	.37	60.2
	Source of control	PB	4	0.99	0.90–1.08	.75	0.0
	Source of control	HB	4	1.35	1.02–1.78	.04	32.0
	Genotyping method	PCR-RFLP	3	1.39	0.89–2.17	.15	35.3
	Genotyping method	Taqman	2	1.13	0.80–1.59	.49	67.1
	Sample acquisition	Peripheral blood	7	1.09	0.92–1.29	.33	36.3
	Sample acquisition	Peripheral blood or frozen prostate tissue	2	1.33	0.70–2.51	.38	63.2
TT vs. CT+CC	Ethnicity	Overall	9	0.94	0.73–1.21	.61	0.0	0.35	0.41
		Caucasian	4	1.83	0.51–6.62	.35	0.0
		Asian	2	1.27	0.67–2.41	.47	0.0
	Source of control	PB	4	0.91	0.68–1.21	.49	0.0
	Source of control	HB	4	1.06	0.61–1.85	.84	0.0
	Genotyping method	PCR-RFLP	3	0.80	0.37–1.69	.55	0.0
	Genotyping method	Taqman	2	0.89	0.66–1.20	.45	0.0
	Sample acquisition	Peripheral blood	7	0.96	0.74–1.26	.79	0.0
	Sample acquisition	Peripheral blood or frozen prostate tissue	2	0.73	0.33–1.60	.43	0.0
TT vs. CC	Ethnicity	Overall	9	0.96	0.74–1.24	.76	0.0	0.35	0.31
		Caucasian	4	1.85	0.51–6.69	.35	0.0
		Asian	2	1.42	0.74–2.74	.30	37.3
	Source of control	PB	4	0.91	0.68–1.21	.50	0.0
	Source of control	HB	4	1.21	0.69–2.14	.51	0.0
	Genotyping method	PCR-RFLP	3	0.88	0.41–1.88	.73	0.0
	Genotyping method	Taqman	2	0.89	0.66–1.20	.45	0.0
	Sample acquisition	Peripheral blood	7	0.98	0.75–1.29	.89	0.0
	Sample acquisition	Peripheral blood or frozen prostate tissue	2	0.80	0.36–1.78	.59	0.0
CT vs.CC	Ethnicity	Overall	9	1.04	0.96–1.13	.37	44.0	0.08	0.08
		Caucasian	4	1.07	0.86–1.34	.53	41.7
		Asian	2	1.27	0.86–1.86	.23	41.2
	Source of control	PB	4	0.99	0.91–1.09	.90	0.0
	Source of control	HB	4	1.40	1.04–1.88	.03	36.7
	Genotyping method	PCR-RFLP	3	1.52	0.89–2.60	.13	49.7
	Genotyping method	Taqman	2	1.13	0.81–1.58	.47	65.0
	Sample acquisition	Peripheral blood	7	1.08	0.92–1.27	.35	28.5
	Sample acquisition	Peripheral blood or frozen prostate tissue	2	1.48	0.66–3.32	.34	73.7

Note. PB = population-based; HB = hospital-based; PCR = polymerase chain reaction; RFLP = restriction fragment length polymorphism.

We couldn’d perform subgroup analyses for subgroups with only one study.

Figure 2.

Forest plot for the association between the CYP19A1 Arg264Cys polymorphism and prostate cancer (T vs. C).

Association Between the CYP19A1 (TTTA)n Repeat Polymorphism and PCa Risk

Six studies (five case-control studies and one nested case-control study) that recruited a total of 1488 cases and 1621 controls were analyzed (Table 2) (Huang et al., 2007; Kachakova et al., 2016; Soni et al., 2012; Sonoda et al., 2010; Suzuki, Nakazato, Matsui, Koike, Okugi, Ohtake, et al., 2003; Tang et al., 2011). Peripheral blood was used in all these studies to detect the (TTTA)n repeat polymorphism. Three of these studies were conducted in Asians and one each in Caucasians, Indians and subjects of mixed ethnicities. The repeat numbers ranged from 7 to 14, but the 9-repeat allele was not detected in four studies (Huang et al., 2007; Sonoda et al., 2010; Suzuki, Nakazato, Matsui, Koike, Okugi, Ohtake, et al., 2003; Tang et al., 2011), and the 14-repeat allele was identified only in one study (Kachakova et al., 2016). Thus, the 7-, 8-, and 10–13-repeat alleles were considered in this meta-analysis. Soni and coworkers (Soni et al., 2012) did not find 10, 11, and 13 repeats either in patients or in controls, so their study could not be included in the analysis of these three alleles. For the same reason, the study of Tang (Tang et al., 2011) was not used in the analysis of the 13-repeat allele.

The pooled results are listed in Table 5. Only the 8-repeat allele was significantly associated with the risk of PCa in the overall population (OR = 1.34, 95% CI = 1.14–1.58, p = .001) (Figure 3), while all the other alleles appeared not related to the overall PCa risk. Among the six studies addressing the 8-repeat allele, one was performed in Caucasians, three in Asians, one in Indians, and one in subjects of mixed ethnicities. Therefore, the subgroup analysis only applied to Asians and yielded a nonsignificant result (OR = 1.27, 95% CI = 0.88–1.85, p = .17). In the subgroup analysis based on the source of controls, the 8-repeat allele was a risk factor for PCa in the PB subgroup (OR = 1.41, 95% CI = 1.13–1.74, p = .002). Although in the subgroup analysis stratified by the genotyping method, the 8-repeat allele increased PCa susceptibility in the subgroup of studies using capillary electrophoresis to investigate the (TTTA)n repeat polymorphism (OR = 1.34, 95% = 1.09–1.65, p = .006), the results should be treated cautiously because there were only two studies using this genotyping method.

Table 5.

Meta-Analysis of the Association Between the CYP19A1 (TTTA)n Repeat Polymorphism and Prostate Cancer.

Repeat number	Subgroup		Study number	Test of association				Publication bias (P)
Repeat number	Subgroup		Study number	OR	95% CI	P	I² (%)	Begg	Egger
7	Ethnicity	Overall	6	0.95	0.86–1.05	.34	17.8	0.06	0.02
	Ethnicity	Asian	3	0.96	0.80–1.15	.66	46.6
	Source of control	PB	2	0.91	0.79–1.05	.21	16.7
	Source of control	HB	3	0.96	0.80–1.15	.66	46.6
	Genotyping method	PCR-RFLP	2	0.93	0.62–1.40	.73	63.2
	Genotyping method	Capillary electrophoresis	2	0.97	0.85–1.11	.65	0.0
8	Ethnicity	Overall	6	1.34	1.14–1.58	.001	0.0	0.06	0.02
	Ethnicity	Asian	3	1.27	0.88–1.85	.17	26.2
	Source of control	PB	2	1.41	1.13–1.74	.002	0.0
	Source of control	HB	3	1.27	0.88–1.85	.21	26.2
	Genotyping method	PCR-RFLP	2	1.36	0.93–1.98	.12	0.0
	Genotyping method	Capillary electrophoresis	2	1.34	1.09–1.65	.006	0.0
10	Ethnicity	Overall	5	1.49	0.94–2.36	.09	11.0	0.81	0.48
	Ethnicity	Asian	3	1.35	0.66–2.83	.41	39.3
	Source of control	HB	3	1.36	0.66–2.83	.41	39.3
	Genotyping method	Capillary electrophoresis	2	1.58	0.88–2.85	.13	12.4
11		Overall	5	0.95	0.84–1.08	.43	9.9	0.46	0.50
		Asian	3	1.02	0.84–1.24	.83	0.0
	Source of control	HB	3	1.02	0.84–1.24	.83	0.0
	Genotyping method	Capillary electrophoresis	2	0.74	0.38–1.45	.38	60.2
12	Ethnicity	Overall	6	0.85	0.64–1.12	.24	52.8	1.00	0.81
	Ethnicity	Asian	3	0.92	0.43–1.96	.83	79.7
	Source of control	PB	2	0.78	0.56–1.10	.16	0.0
	Source of control	HB	3	0.92	0.43–1.96	.83	79.7
	Genotyping method	PCR-RFLP	2	0.64	0.46–0.90	.01	0.0
	Genotyping method	Capillary electrophoresis	2	0.87	0.69–1.11	.27	0.0
13	Ethnicity	Overall	4	1.07	0.64–1.77	.80	0.0	0.31	0.001
		Asian	3	0.95	0.45–2.02	.90	0.0
	Source of control	HB	3	0.95	0.45–2.02	.90	0.0

Note. PB = population-based; HB = hospital-based; PCR = polymerase chain reaction; RFLP = restriction fragment length polymorphism.

We couldn’d perform subgroup analyses for subgroups with only one study.

Figure 3.

Forest plot for the association between the 8-repeat allele in the CYP19A1 (TTTA)n repeat polymorphism and prostate cancer.

Heterogeneity and Sensitivity Analysis

Although there was considerable heterogeneity among the studies in certain subgroups in this meta-analysis (Tables 4 and 5), sensitivity analysis showed that the synthetic results were not materially altered by omitting any single study, indicating the stability of the results (Figures 4 and 5).

Figure 4.

Sensitivity analysis of studies on the CYP19A1 Arg264Cys polymorphism and prostate cancer (T vs. C).

Figure 5.

Sensitivity analysis of studies on the 8-repeat allele in the CYP19A1 (TTTA)n repeat polymorphism and prostate cancer.

Publication Bias

Begg’s funnel plots did not reveal any evidence of obvious asymmetry in studies on the Arg264Cys polymorphism (Figure 6), and Egger’s test with p > .05 further verified the absence of publication bias (Table 4). For the (TTTA)n repeat polymorphism, Begg’s funnel plots and Egger’s test indicated the absence of publication bias except for the 7-, 8-, and 13-repeat alleles (p < .05; Table 5).

Figure 6.

Begg’s funnel plot for studies addressing the CYP19A1 Arg264Cys polymorphism in prostate cancer (T vs. C).

Discussion

The human CYP19A1 gene, a member of the cytochrome P450 superfamily of genes, spans approximately 123 base pairs (bp) and comprises nine translated exons (exons II–X) and one untranslated exon I spliced at the 5’ end and nine introns (Carreau & Hess, 2010; Corbin et al., 1988). Several distinct polymorphisms in the CYP19A1 gene have been studied in PCa, among which the Arg264Cys polymorphism and (TTTA)n repeat polymorphism are the most extensively investigated. Studies on these two polymorphisms in PCa did not provide consistent results, possibly due to the low statistical power of every single study or limited impact of these polymorphisms on PCa. A meta-analysis, a powerful statistical tool, may clarify the conflicting results of previous research and provide a more precise estimation of the impact of the CYP19A1 Arg264Cys and (TTTA)n repeat polymorphisms on PCa (Munafo & Flint, 2004). To the best of our knowledge, this is the first meta-analysis investigating the associations between these two polymorphisms of the CYP19A1 gene and PCa.

The C→T transition (rs700519) in exon 7 of the CYP19A1 gene leads to a single amino acid substitution of Arg by Cys at codon 264, and the T allele has been reported to enhance aromatase enzymatic activity, affecting the conversion of androgens. This modification may alter the risk of several disorders, such as breast cancer, polycystic ovary syndrome (PCOS), and endometrial cancer (Pan et al., 2016; Sun et al., 2015; Tao et al., 2007; Wang et al., 2011). The current meta-analysis failed to detect any association between the Arg264Cys polymorphism and the overall PCa risk. Given the well-established ethnic disparities in PCa incidence, a subgroup analysis based on ethnicity was conducted. No relationship was identified between the Arg264Cys polymorphism and PCa in Caucasians or Asians. Studies were also divided according to the differences between the enrolled control subjects, the sample acquisition and the genotyping method, and the CT+TT and CT genotypes were found to be associated with PCa susceptibility in the subgroup of HB controls. These results should be interpreted with caution, since the relatively low number of studies and small sample sizes in each subgroup prevent statistical interpretation with confidence and do not exclude the possibility that these correlations might be incidental. In addition, evident heterogeneity among the analyzed studies have also weakened the reliability of the results.

The (TTTA)n repeat polymorphism is located at the intron 4 of the CYP19A1 gene, and its effect on the enzymatic activity of aromatase has not been unequivocally established (Celhay et al., 2010; Hammoud et al., 2010). However, this polymorphism may affect mRNA stability or be in linkage disequilibrium with other polymorphisms, including a nearby 3-bp TCT deletion in conjunction with the 7-repeat only and a T/C change in the 3’-untranslated region in which the TT genotype is linked to 8 and longer repeats (Celhay et al., 2010; Olson et al., 2007). The repeat numbers reported in the literature range from 7 to 15, with two major peaks at 7 and 11 or 12 repeats (Fernandez et al., 2014; Hammoud et al., 2010; Xu et al., 2013). Luigi et al. discovered that a high (TTTA)n repeat genotype (10 or more repeats) might be associated with a higher serum level of estradiol (E2) in a group of Italian men older than 55 years (Luigi et al., 2004). Previous studies have demonstrated that the (TTTA)n repeat polymorphism might convert susceptibility to several diseases, including PCOS, gynecomastia, and breast cancer (Ahsan et al., 2004; Izabella et al., 2008; Miyoshi et al., 2000; Xu et al., 2013). In studies related to PCa, Sonoda reported that 11 or more repeats were associated with an increased risk of PCa (Sonoda et al., 2010), while Huang and coworkers identified a similar relationship for homozygous 7-repeats (Huang et al., 2007). Conversely, Soni reported no association between (TTTA)n polymorphism and PCa (Soni et al., 2012). These inconsistent findings might be attributed to discrepancies in ethnicity, country of origin, sample size, phenotypes, type of controls, and genotyping methods. The current meta-analysis uncovered a significant association between the 8-repeat allele and the overall risk of PCa, which was largely driven by studies utilizing PB controls and capillary electrophoresis to detect this polymorphism. On the other hand, the 7-, 10–13-repeat alleles seemed to have nothing to do with PCa risk. English language criterion in literature search, exclusion of studies without adequate amount of data, and the preferential publication of studies that achieved significance might lead to the publication bias detected by Egger’s test in studies on the 8-repeat allele, which is not unusual in meta-analyses (Elias & Joseph, 2008). However, the low heterogeneity and statistically robust findings in sensitivity analysis suggest that the obtained results are relatively reliable.

Several limitations should be taken into consideration. First, the number of eligible studies was limited and the sample sizes were restricted. The number of controls did not match the number of cases in two studies (Modugno et al., 2001; Sarma et al., 2010). These factors may affect the statistical power of the determination of the significance of associations. Second, because of the lack of access to the original data of analyzed studies, it was impossible to adjust for other PCa risk factors such as age, family history, obesity, lifestyle factors, and gene-gene or gene-environment interactions. Third, the inclusion of research published in English with enough data for calculation might have introduced publication bias. Fourth, the nonuniform selection of cases and controls across different studies may also bias the results. A similar effect might have been produced by the deviation from HWE noted in certain studies, possibly due to bias in the selection of control subjects or genotyping errors. Fifth, studies on the Arg264Cys polymorphism were mostly conducted in the Caucasian population. Studies on the (TTTA)n repeat polymorphism have mostly been conducted in Asian populations. These studies were not adequate to identify the genetic etiology of PCa, the prevalence of which varies among racial groups. Well-designed studies with larger sample sizes are warranted to verify the conclusion of the present study.

Conclusions

In summary, this meta-analysis provides evidence of the association between the 8-repeat allele in the CYP19A1 (TTTA)n repeat polymorphism and susceptibility to PCa. Conversely, the Arg264Cys polymorphism in the CYP19A1 gene appeared to have no impact on PCa risk. Further studies are necessary to fully understand the role of these two polymorphisms in PCa, and to facilitate early identification of subjects at high PCa risk.

Footnotes

Acknowledgements

Not applicable.

Authors’ Contributions

LG and YL carried out the data search, selection, and study quality assessment. LL and SS performed the statistical analysis. LG, YL, YC and JG drafted the manuscript. HN conceived the study and participated in critical revision of the manuscript. All authors have read and approved the final version of the manuscript and agreed with the order of presentation of the authors.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Lei Guo

References

Ahsan

Whittemore

A. S.

Chen

Senie

R. T.

Hamilton

S. P.

Wang

Gurvich

Santella

R. M.

(2004). Variants in estrogen-biosynthesis genes CYP17 and CYP19 and breast cancer risk: A family-based genetic association study. Breast Cancer Research, 7(1), R71. https://doi.org/10.1186/bcr951

Boyd

L. K.

Mao

Y. J.

(2012). The complexity of prostate cancer: Genomic alterations and heterogeneity. Nature Reviews. Urology, 9(11), 652–664. https://doi.org/10.1038/nrurol.2012.185

Carreau

Hess

R. A.

(2010). Oestrogens and spermatogenesis. Philosophical Transactions of the Royal Society B, 365(1546), 1517–1535. https://doi.org/10.1098/rstb.2009.0235

Celhay

Yacoub

Irani

Dore

Cussenot

Fromont

(2010). Expression of estrogen related proteins in hormone refractory prostate cancer: Association with tumor progression. The Journal of Urology, 184(5), 2172–2178. https://doi.org/10.1016/j.juro.2010.06.089

Corbin

C. J.

Grahamlorence

Mcphaul

Mason

J. I.

Mendelson

C. R.

Simpson

E. R.

(1988). Isolation of a full-length cDNA insert encoding human aromatase system cytochrome P-450 and its expression in nonsteroidogenic cells. Proceedings of the National Academy of Sciences of the United States of America, 85(23), 8948–8952. https://doi.org/10.1073/pnas.85.23.8948

Cuzick

Thorat

M. A.

Andriole

G. L.

Brawley

O. W.

Brown

P. H.

Culig

Eeles

R. A.

Ford

L. G.

Hamdy

F. C.

Holmberg

(2014). Prevention and early detection of prostate cancer. Lancet Oncology, 15(11), 484–492. https://doi.org/10.1016/S1470-2045(14)70211-6

Egger

Smith

G. D.

Schneider

Minder

C. E.

(1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315(7109), 629–634. https://doi.org/10.1136/bmj.315.7109.629

Elias

Joseph

(2008). Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. Journal of Clinical Epidemiology, 61(7), 634–645. https://doi.org/10.1016/j.jclinepi.2007.12.011

Ellem

S. J.

Schmitt

J. F.

Pedersen

Frydenberg

Risbridger

G. P.

(2004). Local aromatase expression in human prostate is altered in malignancy. The Journal of Clinical Endocrinology and Metabolism, 89(5), 2434–2441. https://doi.org/10.1210/jc.2003-030933

10.

Fernandez

Esteva

Gomezgil

Rumbo

Almaraz

M. C.

Roda

Haromora

Guillamon

Pasaro

(2014). The (CA)n polymorphism of ERβ gene is associated with FtM transsexualism. The Journal of Sexual Medicine, 11(3), 720–728. https://doi.org/10.1111/jsm.12398

11.

Fukatsu

Hirokawa

Araki

Hioki

Murata

Suzuki

Ichikawa

Tsukino

Qiu

Katoh

(2004). Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Research, 24(4), 2431–2437.

12.

Gianfrilli

Pierotti

Pofi

Leonardo

Ciccariello

Barbagallo

(2014). Sex steroid metabolism in benign and malignant intact prostate biopsies: Individual profiling of prostate intracrinology. BioMed Research International, 2014, 464869–464869. https://doi.org/10.1155/2014/464869

13.

Hammoud

A. O.

Griffin

Meikle

A. W.

Gibson

Peterson

C. M.

Carrell

D. T.

(2010). Association of aromatase (TTTAn) repeat polymorphism length and the relationship between obesity and decreased sperm concentration. Human Reproduction, 25(12), 3146–3151. https://doi.org/10.1093/humrep/deq255

14.

Holt

S. K.

Kwon

E. M.

Kolb

Feng

Ostrander

E. A.

Stanford

J. L.

(2013). Association of variants in estrogen-related pathway genes with prostate cancer risk. The Prostate, 73(1), 1–10. https://doi.org/10.1002/pros.22534

15.

Huang

Chen

Lin

Chung

Chang

Huang

W. J. S.

T. T.

Hsu

Yang

Chen

Y. M. A.

(2007). CYP19 TCT tri-nucleotide Del/Del genotype is a susceptibility marker for prostate cancer in a Taiwanese population. Urology, 69(5), 996–1000. https://doi.org/10.1016/j.urology.2007.02.014

16.

Izabella

C. O.

Wojciech

Alina

Michal

Jerzy

(2008). Association between gynecomastia and aromatase (CYP19) polymorphisms. European Journal of Endocrinology, 158(5), 721–727. https://doi.org/10.1530/EJE-07-0556

17.

Kachakova

Mitkova

Popov

Beltcheva

Vlahova

Dikov

Christova

Mitev

Slavov

Kaneva

(2016). Polymorphisms in androgen metabolism genes AR, CYP1B1, CYP19, and SRD5A2and prostate cancer risk and aggressiveness in Bulgarian patients. Turkish Journal of Medical Sciences, 46(3), 626–640. https://doi.org/10.3906/sag-1501-124

18.

Kanda

Tsuchiya

Narita

Inoue

Huang

Chiba

Akihama

Saito

Numakura

Tsuruta

(2015). Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survival. International Journal of Cancer, 136(1), 74–82. https://doi.org/10.1002/ijc.28952

19.

Kicinski

Vangronsveld

Nawrot

T. S.

(2011). An epidemiological reappraisal of the familial aggregation of prostate cancer: A meta-analysis. PLoS One, 6(10), e27130. https://doi.org/10.1371/journal.pone.0027130

20.

Langhorne

, . (1998). Bias in meta-analysis detected by a simple, graphical test. Prospectively identified trials could be used for comparison with meta-analyses. BMJ, 316(7129), 471. https://doi.org/10.1136/bmj.316.7129.469

21.

Liang

Cao

Tian

Shen

Yang

Lin

Zhang

Liu

Shi

(2019). Aromatase-induced endogenous estrogen promotes tumour metastasis through estrogen receptor-α/matrix metalloproteinase 12 axis activation in castration-resistant prostate cancer. Cancer Letters, 467, 72–84. https://doi.org/10.1016/j.canlet.2019.09.001

22.

Luigi

Laura

Daniela

Lucia

Alberto

Annalisa

Carmelo

Francesca

D. M.

Stefano

Barbara

(2004). A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: Effects on bone metabolism. The Journal of Clinical Endocrinology & Metabolism, 89(6), 2803–2810. https://doi.org/10.1210/jc.2003-031342

23.

Miyoshi

Iwao

Ikeda

Egawa

Noguchi

(2000). Breast cancer risk associated with polymorphism in CYP19 in Japanese women. International Journal of Cancer, 89(4), 325–328. https://doi.org/10.1002/1097-0215(20000720)89:4<325::AID-IJC2>3.0.CO;2-3

24.

Modugno

Weissfeld

J. L.

Trump

D. L.

Zmuda

J. M.

Shea

P. R.

Cauley

J. A.

Ferrell

R. E.

(2001). Allelic variants of aromatase and the androgen and estrogen receptors: Toward a multigenic model of prostate cancer risk. Clinical Cancer Research, 7(10), 3092–3096.

25.

Munafo

M. R.

Flint

(2004). Meta-analysis of genetic association studies. Trends in Genetics, 20(9), 439–444. https://doi.org/10.1016/j.tig.2004.06.014

26.

Olson

S. H.

Bandera

E. V.

Orlow

(2007). Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: A HuGE review. American Journal of Epidemiology, 165(3), 235–245. https://doi.org/10.1093/aje/kwk015

27.

Onsory

Sobti

R. C.

Albadran

A. I.

Watanabe

Shiraishi

Krishan

Mohan

Kaur

(2008). Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population. Molecular and Cellular Biochemistry, 314, 25–35. https://doi.org/10.1007/s11010-008-9761-1

28.

Pan

Song

Cao

Cheng

(2016). Genetic polymorphisms and haplotype of hormone-related genes are associated with the risk of breast cancer in Chinese women. Genetics and Molecular Research, 15(2), gmr8640. https://doi.org/10.4238/gmr.15028640

29.

Piovezan

J. M.

Premaor

M. O.

Comim

F. V.

(2019). Negative impact of polycystic ovary syndrome on bone health: A systematic review and meta-analysis. Human Reproduction Update, 25(5), 633–645. https://doi.org/10.1093/humupd/dmz020

30.

Price

D. K.

Chau

C. H.

Till

Goodman

P. J.

Leach

R. J.

Johnsonpais

T. L.

Hsing

A. W.

Hoque

Parnes

H. L.

Schenk

J. M.

(2016). Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the prostate cancer prevention trial. Cancer, 122(15), 2332–2340. https://doi.org/10.1002/cncr.30071

31.

Rahman

Hofland

Foster

P. A.

(2016). In touch with your feminine side: How oestrogen metabolism impacts prostate cancer. Endocrine-Related Cancer, 23(6), R249–R266. https://doi.org/10.1530/ERC-16-0118

32.

Regan

M. M.

Neven

Giobbiehurder

Goldhirsch

Ejlertsen

Mauriac

Forbes

J. F.

Smith

I. E.

Lang

Wardley

A. M.

(2011). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncology, 12(12), 1101–1108. https://doi.org/10.1016/S1470-2045(11)70270-4

33.

Sarma

Dunn

La Ray

Wang

Lange

Cooney

(2010). Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: The Flint Men’s Health Study. Prostate, 68(3), 296–305. https://doi.org/10.1002/pros.20696

34.

Sebastian

Bulun

S. E.

(2001). A highly complex organization of the regulatory region of the human CYP19 (Aromatase) gene revealed by the human genome project. The Journal of Clinical Endocrinology and Metabolism, 86(10), 4600–4602. https://doi.org/10.1210/jcem.86.10.7947

35.

Shenoy

Packianathan

Chen

A. M.

Vijayakumar

(2016). Do African-American men need separate prostate cancer screening guidelines? BMC Urology, 16(1), 19. https://doi.org/10.1186/s12894-016-0137-7

36.

Siegel

R. L.

Miller

K. D.

Jemal

(2018). Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68(1), 7–30. https://doi.org/10.3322/caac.21442

37.

Soni

Bansal

Mishra

A. K.

Batra

Singh

L. C.

Chakraborty

Yadav

D. S.

Mohanty

N. K.

Saxena

(2012). Association of androgen receptor, prostate-specific antigen, and CYP19 gene polymorphisms with prostate carcinoma and benign prostatic hyperplasia in a north Indian population. Genetic Testing and Molecular Biomarkers, 16(8), 835–840. https://doi.org/10.1089/gtmb.2011.0322

38.

Sonoda

Suzuki

Mori

Tsukamoto

Yokomizo

Naito

Fujimoto

Hirao

Miyanaga

Akaza

(2010). Polymorphisms in estrogen related genes may modify the protective effect of isoflavones against prostate cancer risk in Japanese men. European Journal of Cancer Prevention, 19(2), 131–137. https://doi.org/10.1097/CEJ.0b013e328333fbe2

39.

Stang

(2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European Journal of Epidemiology, 25(9), 603–605. https://doi.org/10.1007/s10654-010-9491-z

40.

Sun

Zhu

Liang

De Garibay

G. R.

Yang

(2015). Genetic polymorphisms in estrogen-related genes and the risk of breast cancer among Han Chinese women. International Journal of Molecular Sciences, 16(2), 4121–4135. https://doi.org/10.3390/ijms16024121

41.

Suzuki

Nakazato

Matsui

Koike

Okugi

Kashiwagi

Nishii

Ohtake

Nakata

Ito

(2003). Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer, 98(7), 1411–1416. https://doi.org/10.1002/cncr.11639

42.

Suzuki

Nakazato

Matsui

Koike

Okugi

Ohtake

Takei

Nakata

Hasumi

Yamanaka

(2003). Association of the genetic polymorphism of the CYP19 intron 4 [TTTA]n repeat with familial prostate cancer risk in a Japanese population. Anticancer Research, 23, 4941–4946.

43.

Tang

Yao

Till

Goodman

P. J.

Tangen

C. M.

Kristal

A. R.

Platz

E. A.

Neuhouser

M. L.

Stanczyk

F. Z.

(2011). Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the prostate cancer prevention trial. Carcinogenesis, 32(10), 1500–1506. https://doi.org/10.1093/carcin/bgr139

44.

Tao

Cai

Zhang

Kataoka

Wen

Xiang

Zheng

Shu

(2007). Polymorphisms in the CYP19A1 (Aromatase) gene and endometrial cancer risk in Chinese women. Cancer Epidemiology, Biomarkers & Prevention, 16(5), 943–949. https://doi.org/10.1158/1055-9965.EPI-06-1012

45.

Travis

R. C.

Schumacher

F. R.

Hirschhorn

J. N.

Kraft

Allen

N. E.

Albanes

Berglund

Berndt

S. I.

Boeing

Buenodemesquita

H. B.

(2009). CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the breast and prostate cancer cohort consortium. Cancer Epidemiology, Biomarkers & Prevention, 18(10), 2734–2744. https://doi.org/10.1158/1055-9965.EPI-09-0496

46.

Wang

Yang

Wang

Zhang

Sang

Wang

Zhao

Xing

(2011). A common polymorphism in the human aromatase gene alters the risk for polycystic ovary syndrome and modifies aromatase activity in vitro. Molecular Human Reproduction, 17(6), 386–391. https://doi.org/10.1093/molehr/gar007

47.

Zhang

Xie

Zhang

Shen

Zhang

X. X.

Cao

Wang

Che

Xia

(2013). The (TTTA)n polymorphism in intron 4 of CYP19 and the polycystic ovary syndrome risk in a Chinese population. Molecular Biology Reports, 40(8), 5041–5047. https://doi.org/10.1007/s11033-013-2605-4

The CYP19A1 (TTTA)n Repeat Polymorphism May Affect the Prostate Cancer Risk: Evidence from a Meta-Analysis

Abstract

Keywords

Methods

Literature Search

Inclusion and Exclusion Criteria

Data Extraction and Quality Assessment

Statistical Analysis

Results

Selection and Characteristics of Eligible Studies

Association Between the CYP19A1 Arg264Cys Polymorphism and PCa Risk

Association Between the CYP19A1 (TTTA)n Repeat Polymorphism and PCa Risk

Heterogeneity and Sensitivity Analysis

Publication Bias

Discussion

Conclusions

Footnotes

Acknowledgements

Authors’ Contributions

Declaration of Conflicting Interests

Funding

ORCID iD

References